Evidence map›Paper›PMID 30344406›Full record

ArticleJournal of maxillofacial and oral surgery2018

Co-delivery of 5-Fluorouracil and Curcumin Nanohybrid Formulations for Improved Chemotherapy Against Oral Squamous Cell Carcinoma.

Saurabh Srivastava, Shadab Mohammad, Aditya Bhushan Pant, Prabhat Ranjan Mishra, Gitu Pandey, Shalini Gupta, Sana Farooqui

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of maxillofacial and oral surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Nanoparticles in Dentistry: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  17. Review
  18. Updated Review on the Role of Curcumin in Gastrointestinal Cancers.Advances in experimental medicine and biology · 2021
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Saurabh Srivastava *1Department of Oral and Maxillofacial Surgery, King George's Medical University, Lucknow, UP India.
Shadab Mohammad *1Department of Oral and Maxillofacial Surgery, King George's Medical University, Lucknow, UP India.
Aditya Bhushan Pant2In Vitro Toxicology Laboratory, CSIR-Indian Institute of Toxicology Research, Lucknow, UP India.
Prabhat Ranjan Mishra3Pharmaceutics Division, CSIR-Central Drug Research Institute, Lucknow, UP India.
Gitu Pandey3Pharmaceutics Division, CSIR-Central Drug Research Institute, Lucknow, UP India.
Shalini Gupta4Department of Oral Pathology and Microbiology, King George's Medical University, Lucknow, UP India.
Sana Farooqui1Department of Oral and Maxillofacial Surgery, King George's Medical University, Lucknow, UP India.
King George's Medical University · INCentral Drug Research Institute · INIndian Institute of Toxicology Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe chemotherapeutics agent, 5-fluorouracil (5-FU), and curcumin (Cur), a natural antioxidant, has a wide pharmacological window to treat oral carcinoma; however, both drugs have limited bioavailability. This research study designs to develop a nanoemulsions (NEs) formulation by combining 5-FU and Cur to improve anticancer activity against oral cavity squamous cell carcinoma (OSCC) cells from the diversified origin for in vitro analysis, SCC090 (human tongue) and SCC152 (human hypo-pharynx). METHODOLOGY: NEs formulated through homogenization, applying high-energy ultrasonication technique. The prepared 5-FUNE/Cur-NE/5-FU-Cur-NE were characterized and optimized by different in vitro assays to evaluate release system and treatment of OSCC cells to monitor cellular acceptability, such as in vitro anticancer activity by MTT assay, cell uptake studies and protein expression associated apoptotic study.

results5-FUNE/Cur-NE/5-FU-Cur-NE successfully formulated and show mean-value of the particle size (150-200 nm), surface charge (- 25.70 to - 37.91 mV), and PDI (0.194). In vitro release of 5-FUNE/Cur-NE/5-FU-Cur-NEs was monitored over a course of 04 days, where acidic pH shows higher release as compared to alkaline pH, along with acceptable stability data. Cytotoxicity study has shown higher-dose-dependent anticancer effect with a reduced IC50 value of NEs as compared to BLNE. Cellular uptake study of 5-FUNE/Cur-NE/5-FU-Cur-NEs upgraded many folds, comparatively BLNE and show potential cell arrest. Additionally, the cell protein (Blc2, Bax, P53, and P21) expression was revised and raised cell apoptosis.

conclusionThe combinational loaded, 5-FU and Cur in nanoformulation system have proven their potency to deliver improved anticancer activity, against oral cancer.

Indexed as

5-FluorouracilCurcuminDrug DeliveryNanoparticlesOral cancer

Identifiers

PMID30344406
PMCPMC6181858
OpenAlexW2805599867

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.